ABBV vs BA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Boeing Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
The Boeing Company · Industrials
$217.63
+19.5% upside to fair value
Grade C
QuantHub Verdict
BA has more upside to fair value
(+19.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
BA |
| Current Price |
$208.05 |
$217.63 |
| Fair Value Estimate |
$217.50 |
$260.00 |
| Upside to Fair Value |
+4.5%
|
+19.5%
|
| Market Cap |
$367.9B |
$170.9B |
| Forward P/E |
14.9x
|
74.0x
|
| EV / EBITDA |
16.7x
|
28.4x
|
| Price / Sales |
6.1x
|
1.9x
|
| Price / FCF |
20.9x
|
-88.2x
|
| Revenue Growth YoY |
+8.6%
|
+34.5%
|
| Gross Margin |
83.7%
|
4.8%
|
| Operating Margin |
34.7%
|
-6.1%
|
| Return on Equity |
-129.24%
|
41.0%
|
| Dividend Yield |
3.2% |
0.2% |
| FCF Yield |
4.78%
|
-1.1%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
The Boeing Company is the world's largest aerospace manufacturer operating across commercial airplanes, defense and space, global services, and Boeing Capital. After years of losses stemming from the 737 MAX crisis, production disruptions, and regulatory setbacks, Boeing posted its first profitable year in 2025 with net income of $2.2 billion on revenue of $89.5 billion, a 34.5% revenue increase …
Accumulation Zones
| Metric |
ABBV |
BA |
| Zone Low |
$163.13 |
$195.00 |
| Zone High |
$184.88 |
$221.00 |
| In Buy Zone? |
No
|
Yes
|